gms | German Medical Science

83rd Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

16.05. - 20.05.2012, Mainz

Status of the adjuvant Brachytherapy by lingual area and tongue carcinoma

Meeting Abstract

  • corresponding author Sebastian Wendt - Zentralklinikum, HNO-Klinik, Augsburg, Germany
  • presenting/speaker Nikos Balagiannis - Klinik für Strahlenheilkunde, Augsburg, Germany
  • presenting/speaker Corinna Scharmer - Zentralklinikum, HNO-Klinik, Augsburg, Germany
  • presenting/speaker G. Stüben - Zentralklinikum, HNO-Klinik, Augsburg, Germany
  • presenting/speaker Franz X. Brunner - Zentralklinikum, HNO-Klinik, Augsburg, Germany

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. 83rd Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. Mainz, 16.-20.05.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12hno26

DOI: 10.3205/12hno26, URN: urn:nbn:de:0183-12hno267

Published: July 23, 2012

© 2012 Wendt et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Introduction: The radiation therapy in the case of head-neck tumors is taken its place as adjuvant as well as primary therapy for the treatment of tumor patients.

The TNM-stadium, the location and the general status of the patient are the dominate factors in the aim of the treatment: curative or palliative.

Lingual- and tongue plate squamous cell carcinoma pose as very aggressive tumors. To offer the concerned patients a best possible tumor free survival is a challenge for every oncology surgeon. Interdisciplinary strategies help to reach this goal.

Methods: Our collective of 37 patients with lingual- or tongue plate carcinoma received after surgical tumor treatment with R0 status followed by consecutive percutaneous radiotherapy an adjuvant Boost Brachytherapy with an overall goal of 20 Gy volume doses.

Over 80% did not develop a loco-regional relapse in the first year.

Conclusion: The Brachytherapy especially by tumors in the lingual and tongue area is depicting an important therapy option. Above all in the adjuvant therapy it impresses with a high local dose distribution in the tumor region. The application should be interdisciplinary planned and carried out. Complications like ulcers or exposed bone structures should be treated without delay.